BofA raised the firm’s price target on 10x Genomics (TXG) to $30 from $21 and keeps a Neutral rating on the shares after the company unveiled Atera, a next generation spatial transcriptomics platform enabling in situ whole-transcriptome analysis at single-cell resolution. For now, the firm makes no changes to its revenue assumptions, but it applies a higher multiple, reflecting increased confidence in spatial-driven growth and long-term market expansion, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics announces Atera, a new in situ spatial biology platform
- 10x Genomics price target raised to $30 from $22 at Barclays
- 10x Genomics price target raised to $24 from $18 at Citi
- 10x Genomics upgraded to Outperform from Market Perform at William Blair
- Is Cathie Wood Turning Bearish on Bullish (BLSH) Stock?